This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent data presented at AACR 2025 on adding Perioperative Pembrolizumab to Standard of Care in Patients With Newly Diagnosed Head and Neck Cancer

Ticker(s): MRK

Who's the expert?

Institution: Florida Cancer Specialists

  • Medical Oncologist and Director of Drug Development at Florida Cancer Specialists.
  • Specializes in experimental therapeutics for head, neck and thoracic medical oncology.
  • Previously served as an Associate Professor of Medicine at the University of Miami  where he was a leader for Phase 1 oncology clinical research as well as the Head and Neck Group.

Interview Goal
To discuss data released at AACR 2025 showing that adding Perioperative Pembrolizumab to standard of care improves outcomes in patients with newly diagnosed head and neck cancer.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.